These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 12969956)

  • 1. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention.
    Boot RG; Verhoek M; de Fost M; Hollak CE; Maas M; Bleijlevens B; van Breemen MJ; van Meurs M; Boven LA; Laman JD; Moran MT; Cox TM; Aerts JM
    Blood; 2004 Jan; 103(1):33-9. PubMed ID: 12969956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated plasma chemokine CCL18/PARC in beta-thalassemia.
    Dimitriou E; Verhoek M; Altun S; Karabatsos F; Moraitou M; Youssef J; Boot R; Sarafidou J; Karagiorga M; Aerts H; Michelakakis H
    Blood Cells Mol Dis; 2005; 35(3):328-31. PubMed ID: 16137900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CCL18: a urinary marker of Gaucher cell burden in Gaucher patients.
    Boot RG; Verhoek M; Langeveld M; Renkema GH; Hollak CE; Weening JJ; Donker-Koopman WE; Groener JE; Aerts JM
    J Inherit Metab Dis; 2006 Aug; 29(4):564-71. PubMed ID: 16736095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response.
    Dekker N; van Dussen L; Hollak CE; Overkleeft H; Scheij S; Ghauharali K; van Breemen MJ; Ferraz MJ; Groener JE; Maas M; Wijburg FA; Speijer D; Tylki-Szymanska A; Mistry PK; Boot RG; Aerts JM
    Blood; 2011 Oct; 118(16):e118-27. PubMed ID: 21868580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current development and usefulness of biomarkers for Gaucher disease follow up].
    Maire I; Guffon N; Froissart R
    Rev Med Interne; 2007 Oct; 28 Suppl 2():S187-92. PubMed ID: 18228687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma chitotriosidase activity versus CCL18 level for assessing type I Gaucher disease severity: protocol for a systematic review with meta-analysis of individual participant data.
    Raskovalova T; Deegan PB; Yang R; Pavlova E; Stirnemann J; Labarère J; Zimran A; Mistry PK; Berger M
    Syst Rev; 2017 Apr; 6(1):87. PubMed ID: 28427477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma chitotriosidase and CCL18: early biochemical surrogate markers in type B Niemann-Pick disease.
    Brinkman J; Wijburg FA; Hollak CE; Groener JE; Verhoek M; Scheij S; Aten J; Boot RG; Aerts JM
    J Inherit Metab Dis; 2005; 28(1):13-20. PubMed ID: 15702402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma chitotriosidase and CCL18 as surrogate markers for granulomatous macrophages in sarcoidosis.
    Boot RG; Hollak CE; Verhoek M; Alberts C; Jonkers RE; Aerts JM
    Clin Chim Acta; 2010 Jan; 411(1-2):31-6. PubMed ID: 19808030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mass spectrometric quantification of glucosylsphingosine in plasma and urine of type 1 Gaucher patients using an isotope standard.
    Mirzaian M; Wisse P; Ferraz MJ; Gold H; Donker-Koopman WE; Verhoek M; Overkleeft HS; Boot RG; Kramer G; Dekker N; Aerts JM
    Blood Cells Mol Dis; 2015 Apr; 54(4):307-14. PubMed ID: 25842368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and use of biomarkers in Gaucher disease and other lysosomal storage diseases.
    Aerts JM; Hollak CE; van Breemen M; Maas M; Groener JE; Boot RG
    Acta Paediatr Suppl; 2005 Mar; 94(447):43-6; discussion 37-8. PubMed ID: 15895711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCL18 as an alternative marker in Gaucher and Niemann-Pick disease with chitotriosidase deficiency.
    Chang KL; Hwu WL; Yeh HY; Lee NC; Chien YH
    Blood Cells Mol Dis; 2010 Jan; 44(1):38-40. PubMed ID: 19819171
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease.
    Deegan PB; Moran MT; McFarlane I; Schofield JP; Boot RG; Aerts JM; Cox TM
    Blood Cells Mol Dis; 2005; 35(2):259-67. PubMed ID: 16125420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy.
    van Dussen L; Hendriks EJ; Groener JE; Boot RG; Hollak CE; Aerts JM
    J Inherit Metab Dis; 2014 Nov; 37(6):991-1001. PubMed ID: 24831585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of plasma chitotriosidase activity, CCL18/PARC concentration and NP-C suspicion index in the diagnosis of Niemann-Pick disease type C: a prospective observational study.
    De Castro-Orós I; Irún P; Cebolla JJ; Rodriguez-Sureda V; Mallén M; Pueyo MJ; Mozas P; Dominguez C; Pocoví M;
    J Transl Med; 2017 Feb; 15(1):43. PubMed ID: 28222799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limitations in quantitation of the biomarker CCL18 in Gaucher disease blood samples by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.
    van Breemen MJ; Bleijlevens B; de Koster CG; Aerts JM
    Biochim Biophys Acta; 2006 Oct; 1764(10):1626-32. PubMed ID: 17010683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current and future biochemical markers for Gaucher disease].
    Froissart R
    Rev Med Interne; 2006 Mar; 27 Suppl 1():S22-5. PubMed ID: 16644397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LC-MS/MS analysis of plasma glucosylsphingosine as a biomarker for diagnosis and follow-up monitoring in Gaucher disease in the Spanish population.
    Irún P; Cebolla JJ; López de Frutos L; De Castro-Orós I; Roca-Espiau M; Giraldo P
    Clin Chem Lab Med; 2020 Apr; 58(5):798-809. PubMed ID: 32126008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different dose-dependent correction of MIP-1beta and chitotriosidase during initial enzyme replacement therapy.
    van Breemen MJ; de Fost M; Maas M; Wiersma MG; Hollak CE; Poll LW; Vom Dahl S; Boot RG; Aerts JM
    J Inherit Metab Dis; 2009 Apr; 32(2):274-9. PubMed ID: 19255873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ten years' experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher disease.
    Erikson A; Forsberg H; Nilsson M; Aström M; Månsson JE
    Acta Paediatr; 2006 Mar; 95(3):312-7. PubMed ID: 16497642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma chitotriosidase activity in Gaucher disease patients who have been treated either by bone marrow transplantation or by enzyme replacement therapy with alglucerase.
    Young E; Chatterton C; Vellodi A; Winchester B
    J Inherit Metab Dis; 1997 Aug; 20(4):595-602. PubMed ID: 9266398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.